Search peptides, terms, sources/
Melanocortin

Afamelanotide

Synthetic alpha-MSH analogue studied in erythropoietic protoporphyria (EPP). Licensed in the UK for adults with EPP; not recommended for routine NHS use. Not the same as Melanotan II.

UK status and evidence last reviewed .

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Moderate evidence (level 3 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the medicine.

1 finding at this grade. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations, and none of them means a product is safe to obtain or use.

UK status
Licensed UK medicineChecked
Best study type
Human trials1 human trial · 2 human observational

What is Afamelanotide?

Afamelanotide is a synthetic analogue of alpha-melanocyte-stimulating hormone that raises skin melanin by acting on the melanocortin-1 receptor, studied as a way to reduce painful light reactions in erythropoietic protoporphyria (EPP). It is licensed in the UK for adults with EPP, and two placebo-controlled phase 3 trials in 168 adults measured more pain-free time in direct sunlight, but NICE and the Scottish Medicines Consortium did not recommend routine NHS use.

Its UK licence is for preventing phototoxicity in adults with EPP. It acts on the melanocortin-1 receptor (MC1R), and it is a different molecule from Melanotan II.

Class
Melanocortin-1 receptor agonist (alpha-MSH analogue)
Origin
Analogue / modified
UK status
Licensed UK medicine
Best study type
Human trials
Evidence last reviewed

How does Afamelanotide work?

A 2026 review states that afamelanotide raises skin melanin by acting directly on the melanocortin-1 receptor (MC1R). In EPP, an inherited condition in which light causes severe pain and skin reactions, the aim is more pigment so people can tolerate more time in sunlight. The trials measured pain-free time in sunlight, not a change to the underlying inherited defect.

The mechanism in more detail

Afamelanotide is a synthetic analogue of alpha-MSH, the natural hormone that signals melanocytes (pigment cells) to make melanin. A 2026 review states that it raises skin melanin content by targeting the melanocortin-1 receptor (MC1R) directly. In erythropoietic protoporphyria (EPP), an inherited condition in which light exposure causes severe pain and skin reactions, the aim is to increase pigment so that people can tolerate more time in sunlight. The trials measured pain-free time in direct sunlight, not a change to the underlying inherited defect.

Not the same as Melanotan II. Afamelanotide and Melanotan II are both melanocortin-receptor agonists, but they are different molecules with very different regulatory positions. This site describes Melanotan II as a non-selective agonist that acts on several melanocortin receptors, including MC1R (tanning) and MC4R (erectile and libido effects), and no Melanotan II product holds a UK marketing authorisation. Afamelanotide is described in the literature as acting directly on MC1R, and it is a licensed UK medicine for one rare condition. Evidence on one of the two must not be applied to the other.

Setmelanotide, a licensed MC4R-selective peptide on this site, also darkens skin, which its product information attributes to weaker activity at MC1R. A 2026 review calls this a bystander effect, as opposed to the direct MC1R targeting of afamelanotide.

Classification and structure

Names
Afamelanotide; Scenesse (brand name); NDP-alpha-MSH; NDP-MSH; Melanotan I
Class
Melanocortin-1 receptor agonist (alpha-MSH analogue)
Origin
Analogue / modified
Structure
Synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH), also written NDP-alpha-MSH. Published reviews describe it as a first-in-class synthetic alpha-MSH analogue.
Routes used in the research
Subcutaneous implant in the trials cited.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

Afamelanotide has 5 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

5 findings

Counts recorded findings by grade. It does not rate the medicine.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
12101

Two phase 3 trials in EPP Moderate

Two multicentre, randomised, double-blind, placebo-controlled trials in adults with EPP tested afamelanotide given as a subcutaneous implant (74 people in the European Union trial, 94 in the US trial). The primary outcome was hours of direct sunlight with no pain. In the US trial, median pain-free sunlight time at 6 months was 69.4 hours versus 40.8 hours on placebo (P = 0.04). In the EU trial, at 9 months it was 6.0 hours versus 0.8 hours (P = 0.005), with fewer phototoxic reactions (77 versus 146; P = 0.04). Quality of life improved in both trials, and adverse events were mostly mild.

Study type
Human trial
Population
168 adults with erythropoietic protoporphyria (EU trial n=74; US trial n=94); randomised, double-blind, placebo-controlled.
Source
1 Langendonk et al., 2015

Limitation: Funded by the manufacturer and others.

Limitations in full

Funded by the manufacturer and others. Two trials of moderate size with different lengths and endpoints, in a rare condition. Both NHS Scotland and NHS England decided not to recommend routine use (see the NHS recommendations finding below).

Long-term observational study Limited

In an observational study of 115 patients with EPP who received 1,023 implants over up to 8 years, a quality-of-life score rose from 31% of the maximum before treatment to 74% after starting. About 23% stopped treatment, mostly for reasons such as pregnancy or financial restrictions. Only minor adverse events attributed to afamelanotide were recorded, mainly nausea.

Study type
Human observational
Population
115 patients with erythropoietic protoporphyria followed for up to 8 years.
Source
2 Biolcati et al., 2015

Limitation: Observational with no control group.

Limitations in full

Observational with no control group. The quality-of-life score is self-reported, so placebo effects and selection of continuing patients cannot be excluded.

Vitamin D levels Limited

In a multicentre cohort of 230 patients with EPP (1,774 vitamin D measurements, 2005 to 2021), vitamin D deficiency persisted in 71.8% despite afamelanotide treatment. Afamelanotide alone was not linked to a significant rise in vitamin D (beta 0.5, 95% CI -3.2 to 4.2), whereas cholecalciferol (vitamin D3) was (beta 11.6, 95% CI 7.2 to 15.9).

Study type
Human observational
Population
230 patients with erythropoietic protoporphyria; multicentre cohort.
Source
3 Kluijver et al., 2024

Limitation: Cohort study, not randomised.

Limitations in full

Cohort study, not randomised. Shows what happened to vitamin D levels, not whether the extra pigment has any wider health effect.

NHS recommendations: England and Scotland Not graded

The Scottish Medicines Consortium (advice published 8 February 2021) did not recommend afamelanotide for routine use in NHS Scotland, finding the company's justification of cost relative to benefit insufficient, but allowed prescribing through the ultra-orphan pathway while more evidence is gathered. In England, NICE guidance HST27 (published 26 July 2023) also does not recommend it; a peer-reviewed analysis of 29 NICE highly specialised technology decisions lists afamelanotide for EPP as the one negative decision.

Study type
Government guidance
Population
Not applicable; health technology assessment decisions.
Source
4 Scottish Medicines Consortium (SMC), 2021

Limitation: These are NHS access decisions, not licensing decisions.

Limitations in full

These are NHS access decisions, not licensing decisions. The SMC advice is read directly; the NICE recommendation is confirmed from a peer-reviewed analysis of NICE decisions (Barman-Aksozen et al., 2024, PMID 38791830), because the NICE web page could not be opened by our checking tools on 2026-11-14.

Mechanism of action Preliminary

A 2026 review in a German dermatology journal states that afamelanotide (NDP-alpha-MSH) increases skin melanin content by targeting MC1R directly, and notes that it is approved in Germany. It contrasts this with setmelanotide, whose skin-darkening effect is described as a bystander effect.

Study type
Narrative review
Population
Review of pigmentation biology; not a clinical population.
Source
5 Bohm, 2026

Limitation: Review article from the abstract only (full text behind a subscription).

Limitations in full

Review article from the abstract only (full text behind a subscription). Adequate for mechanism background, not for any efficacy claim.

What safety findings have been reported?

3 safety findings are recorded for Afamelanotide. A short list does not mean a substance is safe; it reflects what has been studied and reported.

Adverse events in the phase 3 trials

In the two phase 3 EPP trials, adverse events were mostly mild, and the serious adverse events were not thought to be related to the drug; the authors described the side-effect and adverse-event profile as acceptable.

Source
1 Langendonk et al., 2015

Long-term adverse events

In 115 patients followed for up to 8 years, only minor adverse events attributable to afamelanotide were recorded, predominantly nausea.

Source
2 Biolcati et al., 2015

Moles (naevi) under dermoscopy

In a small dermoscopy study of 15 patients with 103 acquired moles, focal thickening of the mole pigment network appeared at about 5 months in some moles and returned to baseline by 12 months. The authors reported no findings suggesting malignant change and no new moles.

Source
6 Arisi et al., 2021

What is Afamelanotide's UK regulatory status?

Marketing authorisation
Licensed in the UK for one rare condition. Afamelanotide appears on the MHRA Products database active-substance index (checked 14 November 2026). The Scottish Medicines Consortium record names Clinuvel (UK) Ltd as the company.
Prescription status
Legal category not confirmed: the electronic Medicines Compendium has no entry for afamelanotide on 14 November 2026, so no UK product record giving a legal category could be read.
Medicine class
Licensed medicinal product.
MHRA position
On the MHRA Products database active-substance index (checked 14 November 2026). This differs from Melanotan II, no product of which holds a UK marketing authorisation.
Authorised use
Prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP), as worded in the Scottish Medicines Consortium record.
Other restrictions
NHS access is separate from the licence. NICE guidance HST27 (26 July 2023) does not recommend afamelanotide for NHS use in England, and the Scottish Medicines Consortium (8 February 2021) did not recommend it for routine use in NHS Scotland, though it can be prescribed there through the ultra-orphan pathway.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations, and none of them means a product is safe to obtain or use.

References

7 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, et al. (2015). Afamelanotide for Erythropoietic Protoporphyria. New England Journal of MedicineHuman clinical trial, RCT · DOI 10.1056/NEJMoa1411481 · PMID 26132941 · Original ↗
  2. Biolcati G, Marchesini E, Sorge F, Barbieri L, Schneider-Yin X, Minder EI (2015). Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. British Journal of DermatologyHuman observational · DOI 10.1111/bjd.13598 · PMID 25494545 · Original ↗
  3. Kluijver LG, Nekouei Shahraki M, Wagenmakers MAEM, et al. (2024). The effects of cholecalciferol and afamelanotide on vitamin D levels in erythropoietic protoporphyria: a multicentre cohort study. British Journal of DermatologyHuman observational · DOI 10.1093/bjd/ljae148 · PMID 38634774 · Original ↗
  4. Scottish Medicines Consortium (SMC) (2021). Afamelanotide (Scenesse): advice on prevention of phototoxicity in adult patients with erythropoietic protoporphyria (SMC ID 1251/17). Scottish Medicines Consortium · Original ↗
  5. Bohm M (2026). Hormones and skin pigmentation: fundamentals and clinical relevance (English title as indexed by Europe PMC). Dermatologie (Heidelberg)Narrative review · DOI 10.1007/s00105-025-05636-4 · PMID 41489668 · Original ↗
  6. Arisi M, Rossi M, Rovati C, et al. (2021). Clinical and dermoscopic changes of acquired melanocytic nevi of patients treated with afamelanotide. Photochemical & Photobiological SciencesHuman observational · DOI 10.1007/s43630-021-00020-2 · PMID 33721252 · Original ↗
  7. Medicines and Healthcare products Regulatory Agency (MHRA) (2026). MHRA Products database: active substance index (A to Z), checked 14 November 2026. MHRA Products database · Original ↗

Questions about Afamelanotide

What is Afamelanotide?

Afamelanotide is a synthetic analogue of alpha-melanocyte-stimulating hormone that raises skin melanin by acting on the melanocortin-1 receptor, studied as a way to reduce painful light reactions in erythropoietic protoporphyria (EPP). It is licensed in the UK for adults with EPP, and two placebo-controlled phase 3 trials in 168 adults measured more pain-free time in direct sunlight, but NICE and the Scottish Medicines Consortium did not recommend routine NHS use. Read what it is.

Is Afamelanotide licensed in the UK?

PeptGuru records Afamelanotide's UK status as: Licensed UK medicine. The licensed products and their approved uses are listed in the UK status section. UK status checked 14 November 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on Afamelanotide show?

PeptGuru records 5 research findings for Afamelanotide: 1 from a human trial, 2 from human observational studies and 2 from regulatory or other records. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for Afamelanotide?

3 safety findings are recorded, including: adverse events in the phase 3 trials; long-term adverse events; moles (naevi) under dermoscopy. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for Afamelanotide?

All 7 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • New profile · Afamelanotide added: 5 findings and 3 safety items, each checked against its published record, with UK status checked on the MHRA register.

How findings are graded: the grading method. All changes.

  • Melanotan IIMT-II

    Synthetic melanocortin receptor agonist studied for skin tanning. Not licensed in the UK; human evidence is a three-volunteer pilot plus case reports.

    MelanocortinHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • PT-141 (Bremelanotide)Bremelanotide

    No UK marketing authorisation found; authorised in the US. Selective melanocortin-4 receptor agonist studied for low sexual desire in women.

    MelanocortinHuman trialsEvidence reviewed
    StrongNot licensed in the UK
  • Setmelanotide

    Synthetic peptide that activates the MC4 receptor, studied in rare forms of obesity. UK prescription-only medicine for three rare conditions; trials were small and do not cover common obesity.

    MelanocortinHuman trialsEvidence reviewed
    ModerateLicensed UK medicine

Compare Afamelanotide with Melanotan II

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.